

**Advanced breast cancer: diagnosis and management (Partial update)**

**Date:** 09/05/2025

**Location:** Virtual

**Minutes:** FINAL

**Committee members present:**

Adam Firth	Chair	Present for notes 1 - 6
Karen Lockwood	Lay member	Present for notes 1 - 6
Simon Lowes	Radiologist	Present for notes 1 - 6
Madeleine Meynell	Lay member	Present for notes 1 - 6
Mitesh Naik	Radiologist	Present for notes 1 - 6
Tim Robinson	Medical oncologist	Present for notes 1 - 6
Clare Sacco	Lay member	Present for notes 1 - 6
Elinor Sawyer	Clinical oncologist	Present for notes 1 - 6
Ben Thwaites	Pharmacist	Present for notes 1 - 6
Caroline Tweedie	Clinical Nurse Specialist	Present for notes 1 - 6

**In attendance:**

Adefisayo Abba-Abba	Technical Analyst	Present for notes 1 - 6
Victoria Carter	Implementation Support Manager	Present for notes 1 - 6
Olivia Crane	Senior Technical Analyst	Present for notes 1 - 6
Gareth Haman	Senior Guidance Content Designer	Present for notes 1 - 6
Marie Harrisingh	Topic Lead	Present for notes 1 - 6
James Hawkins	Health Economics Adviser	Present for notes 1 - 6
Tzujung Lai	Health Economist	Present for notes 1 - 6
Yolanda Martinez	Technical Analyst	Present for notes 1 - 6
Adam O'Keefe	Project Manager	Present for notes 1 - 6
Adam Storrow	Business Analyst, Resource Impact Assessment	Present for notes 1 - 6

**Apologies:**

Ramsey Cutress	Topic Adviser
Mark Davies	Medical oncologist
Milly Finch	Pharmacist
Andrea Heath	Senior Information Specialist, NICE

Katherine Saxby

Medicines Adviser, NICE

### **1. Welcome, introductions and apologies**

The Chair welcomed the committee members and NICE attendees to the second committee meeting for the partial update to the NICE Advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

### **2. Declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Advanced breast cancer.

The Chair asked committee members to verbally declare any new interests, the following new interests were declared:

Name	Declaration	Date DOI arose	Action
Tim Robinson	Renumerated role with Novartis advising on the development of teaching materials on breast cancer - topics as yet unknown.	May 2025	Declare and participate pending confirmation of topics
Tim Robinson	Renumerated ad board advising on Nordic Pharma's product Teysuno and its potential role in breast cancer as a replacement for capecitabine in those intolerant.	May 2025	Non-specific.  Declare and participate.

The Chair and a senior member of the Developer's team noted that neither this interest nor any previously declared interests would prevent attendees from fully participating in the meeting.

### **3. Minutes of the previous meeting**

The minutes of the previous meeting were ratified as an accurate record.

**4. Review protocol for diagnosis of metastatic breast cancer using PET CT and CT**

The Chair introduced Technical Analyst Adefisayo Abba-Abba, who sought the committee's input on the draft review protocol for the planned Review Question on diagnosis of metastatic breast cancer using PET CT and CT.

**5. Review protocol for monitoring response to treatment and disease progression of metastatic breast cancer using PET-CT**

The Chair introduced NICE Senior Technical Analyst Olivia Crane, who sought the committee's input on the draft review protocol for the planned Review Question on monitoring response to treatment and disease progression of metastatic breast cancer using PET-CT.

**6. AOB, Summary and next steps**

The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, the Chair brought the meeting to a close.

**Date of next meeting:** 06/06/2025

**Location of next meeting:** Virtual